This observational clinical study characterizes pain and autonomic symptoms in patients with Parkinson's disease (PD) and atypical Parkinsonian syndromes, including Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), and Corticobasal Syndrome (CBS). The study investigates the prevalence, mechanisms, and impact of these non-motor symptoms on quality of life, addressing a critical gap in the understanding of these often underrecognized manifestations of neurodegenerative disorders.
Non-motor symptoms have emerged as a major determinant of quality of life in parkinsonian syndromes, often preceding motor symptoms by years and contributing significantly to disease burden. Among these, pain and autonomic dysfunction represent two of the most prevalent yet understudied non-motor manifestations, affecting the majority of patients throughout the disease course.
| Field |
Value |
| NCT ID |
NCT05748028 |
| Status |
Recruiting |
| Study Type |
Observational |
| Conditions |
Parkinson's Disease, PSP, MSA, CBS, Atypical Parkinsonism |
| Enrollment |
Target 200 participants |
| Primary Outcome |
Prevalence and characteristics of pain and autonomic symptoms |
Pain is a common and underrecognized non-motor symptom that significantly impacts quality of life, functional capacity, and treatment outcomes in parkinsonian disorders. The pathogenesis of pain in these conditions is multifactorial, involving dopaminergic dysfunction, neuroinflammation, sensory pathway involvement, and secondary effects from motor symptoms.
Prevalence
Pain affects a substantial proportion of patients across all parkinsonian syndromes:
- Parkinson's Disease: 30-80% of patients experience pain during their disease course, making it one of the most common non-motor symptoms
- Progressive Supranuclear Palsy: 50-70% of patients report significant pain, often related to axial rigidity and dystonia
- Multiple System Atrophy: Pain prevalence is similar to PSP, with additional contributions from autonomic dysfunction
- Corticobasal Syndrome: Pain is frequently related to asymmetric limb rigidity and dystonia
Pain Classification
The pain experienced by patients with parkinsonian syndromes can be categorized into several distinct types:
-
Musculoskeletal Pain
- Related to rigidity, bradykinesia, and akinesia
- Often manifests as diffuse body aches or localized pain in joints
- Worsened by immobility and improved with dopaminergic therapy
- Common in neck, shoulders, lower back, and knees
-
Neuropathic Pain
- Characterized by burning, shooting, or electric shock-like sensations
- May result from nerve damage or central sensory pathway involvement
- Often less responsive to standard dopaminergic therapy
- May involve thalamic pain syndrome (central pain)
-
Dystonic Pain
- Associated with sustained muscle contractions and abnormal postures
- Common in foot dystonia, cervical dystonia, and blepharospasm
- Often correlates with "off" periods in PD patients
-
Akathisia
- Restlessness and inability to remain still
- May be confused with motor restlessness or tardive dyskinesia
- Can significantly impact daily functioning
Mechanisms of Pain
The pathophysiological mechanisms underlying pain in parkinsonian syndromes include:
-
Dopaminergic Dysfunction
- Loss of dopaminergic neurons in the substantia nigra affects pain processing
- The basal ganglia play a key role in pain perception and modulation
- Dopaminergic therapy may modulate pain thresholds
-
Neuroinflammation
- Microglial activation in pain processing regions
- Elevated pro-inflammatory cytokines (TNF-α, IL-1β, IL-6)
- Involvement of brainstem pain modulatory pathways
-
Sensory Pathway Involvement
- Thalamic dysfunction affecting sensory processing
- Spinal cord involvement in some cases
- Small fiber neuropathy in certain conditions
-
Secondary Pain Mechanisms
- Pain secondary to rigidity and abnormal postures
- Pain from falls and injuries related to postural instability
- Pain from musculoskeletal complications of akinesia
Autonomic impairment is a core feature of parkinsonian syndromes, with significant variations in presentation and severity across different disorders. Autonomic dysfunction often serves as a differential diagnostic feature and may precede motor symptoms in some cases.
Autonomic Dysfunction in Progressive Supranuclear Palsy
PSP is characterized by relatively mild to moderate autonomic dysfunction compared to MSA:
-
Orthostatic Hypotension
- Present in approximately 50-70% of PSP patients
- Typically less severe than in MSA
- May be exacerbated by medications
- Contributes to falls and syncope risk
-
Urinary Dysfunction
- Urinary urgency and frequency are common
- Nocturia frequently disrupts sleep
- Less commonly progresses to urinary incontinence
-
Constipation
- Very common, often predating motor symptoms
- Related to enteric nervous system involvement
- May respond to dietary modifications and laxatives
-
Sleep Disorders
- REM sleep behavior disorder is less common than in PD
- Sleep fragmentation is frequent
- Obstructive sleep apnea may be present
Autonomic Dysfunction in Multiple System Atrophy
MSA is characterized by severe autonomic failure, which is a hallmark feature of the disorder:
-
Neurogenic Orthostatic Hypotension
- Present in the majority of MSA patients
- Often severe and symptomatic
- Results from failure of sympathetic vasoconstrictor neurons
- May cause recurrent syncope
-
Urinary Incontinence
- Urinary incontinence is a key diagnostic feature
- Detrusor overactivity is common
- Often requires management with anticholinergic medications or intermittent catheterization
-
Erectile Dysfunction
- Common in male patients
- Often an early symptom
- May precede motor symptoms by years
-
Gastrointestinal Dysfunction
- Severe constipation is universal
- Gastroparesis may occur
- Weight loss can be significant
Autonomic Dysfunction in Parkinson's Disease
Autonomic dysfunction in PD is generally mild to moderate:
- Orthostatic hypotension affects 30-50% of patients
- Urinary symptoms are common but usually less severe
- Constipation is very common and often early
- Sexual dysfunction may occur
Autonomic Dysfunction in Corticobasal Syndrome
CBS shows variable autonomic involvement:
- Orthostatic hypotension may be present
- Urinary dysfunction occurs in some patients
- Less studied than in other parkinsonian syndromes
The study aims to systematically characterize:
- Pain Prevalence and Characteristics: Determine the prevalence of different pain types and their clinical features across diagnostic groups
- Autonomic Symptom Burden: Quantify the severity and distribution of autonomic symptoms
- Correlation with Disease Severity: Examine relationships between non-motor symptoms and motor disease severity
Additional analyses will assess:
- Quality of Life Impact: Evaluate how pain and autonomic symptoms affect functional status and quality of life
- Comparison Across Diagnoses: Compare the profile of non-motor symptoms across PD, PSP, MSA, and CBS
- Treatment Response Patterns: Examine relationships between dopaminergic therapy and non-motor symptom severity
- Biomarker Correlations: Where available, examine correlations with disease biomarkers
The study employs validated instruments for comprehensive pain assessment:
-
Visual Analog Scale (VAS)
- Subjective pain intensity measurement
- 0-100 mm scale
- Quick and widely used
-
King's Parkinson's Disease Pain Scale (KPPS)
- Disease-specific pain assessment
- Covers seven pain domains
- Validated for PD and adapted for other parkinsonian syndromes
-
McGill Pain Questionnaire
- Comprehensive pain assessment
- Sensory, affective, and evaluative dimensions
- Provides detailed pain characterization
-
DN4 Questionnaire
- Screening tool for neuropathic pain
- Ten items assessing sensory descriptors and examination findings
- Helps differentiate neuropathic from nociceptive pain
-
Brief Pain Inventory (BPI)
- Assesses pain severity and interference
- Widely validated across conditions
- Useful for functional impact assessment
Comprehensive autonomic assessment includes:
-
Composite Autonomic Scoring System (CASS)
- Quantitative measure of autonomic function
- Assesses sudomotor, adrenergic, and cardiovagal function
- Provides severity grading
-
SCOPA-AUT
- Self-administered autonomic questionnaire
- Covers six domains: gastrointestinal, urinary, cardiovascular, thermoregulatory, pupillomotor, and sexual
- Validated for Parkinson's disease
-
Orthostatic Vital Signs
- Blood pressure and heart rate in supine and standing positions
- Classic test for orthostatic hypotension
- Simple and informative
-
Heart Rate Variability (HRV)
- Measure of cardiac autonomic modulation
- Reduced HRV indicates autonomic dysfunction
- Non-invasive assessment tool
-
Quantitative Sudomotor Axon Reflex Test (QSART)
- Evaluates sudomotor function
- Useful for small fiber neuropathy detection
- Available in specialized centers
Understanding pain in parkinsonian syndromes has important therapeutic implications:
-
Dopaminergic Therapy Optimization
- Pain that improves with dopaminergic therapy suggests dopaminergic mechanism
- Motor fluctuations may correlate with pain fluctuations
- Continuous dopaminergic stimulation may provide more stable pain control
-
Targeted Interventions
- Musculoskeletal pain: Physical therapy, exercise, analgesics
- Neuropathic pain: Gabapentin, pregabalin, duloxetine
- Dystonic pain: Botulinum toxin injections, medication adjustments
-
Non-Pharmacological Approaches
- Physical therapy and exercise programs
- Occupational therapy for functional adaptation
- Cognitive-behavioral approaches for chronic pain management
Autonomic dysfunction requires specific management strategies:
-
Orthostatic Hypotension
- Increased salt and fluid intake
- Compression stockings
- Head-of-bed elevation
- Fludrocortisone or midodrine in severe cases
-
Urinary Dysfunction
- Bladder training techniques
- Anticholinergic medications (caution in cognitive impairment)
- Intermittent catheterization for severe cases
-
Constipation
- High-fiber diet
- Adequate hydration
- Regular exercise
- Osmotic laxatives as needed
¶ Expected Findings and Clinical Impact
The study is expected to provide:
- Prevalence Data: Comprehensive prevalence rates for different pain types across diagnostic categories
- Autonomic Symptom Profiles: Detailed characterization of autonomic symptom burden in each condition
- Diagnostic Differentiators: Identification of non-motor features that help differentiate between parkinsonian syndromes
- Treatment Implications: Insights into how current treatments affect non-motor symptoms
The results of this study will inform:
- Clinical Practice Guidelines: Evidence-based recommendations for non-motor symptom assessment and management
- Patient Care: Improved detection and treatment of pain and autonomic symptoms
- Research Priorities: Identification of gaps in knowledge to guide future research
- Drug Development: Understanding of non-motor symptoms as potential therapeutic targets
| Study |
Year |
Key Finding |
| Defaye et al. |
2022 |
Pain prevalence 40-85% in PD, higher than previously recognized |
| Wu et al. |
2019 |
Pain in PSP correlates with disease severity and axial symptoms |
| Chaudhuri et al. |
2010 |
Non-motor symptoms bundle includes pain as core feature |
| Study |
Year |
Key Finding |
| Goldstein et al. |
2006 |
Autonomic dysfunction helps differentiate MSA from PD |
| Sachdev et al. |
2015 |
Autonomic symptoms in PSP correlate with disease progression |
| Khoo et al. |
2016 |
Non-motor symptoms in PSP are prevalent and disabling |
The basal ganglia play a critical role in pain processing. In Parkinson's disease and related disorders, dopaminergic degeneration disrupts normal pain modulation:
Dopaminergic Pain Modulation
- The substantia nigra pars compacta projects to the striatum, which modulates pain perception through thalamic and cortical pathways
- Loss of dopaminergic neurons reduces endogenous pain inhibition
- This explains why dopaminergic medications can sometimes improve pain in PD
Thalamic Involvement
- The ventrolateral thalamus receives altered input from the basal ganglia
- This can lead to thalamic pain syndrome (Dejerine-Roussy syndrome)
- Characterized by contralateral hemibody pain, allodynia, and hyperalgesia
Neuroinflammation Role
- Microglial activation in the substantia nigra and spinal cord
- Pro-inflammatory cytokines (IL-1β, TNF-α, IL-6) contribute to central sensitization
- Peripheral inflammation may exacerbate central pain mechanisms
Musculoskeletal Contributions
- Rigid muscles and dystonia create chronic mechanical stress
- Abnormal postures lead to joint degeneration
- Falls and injuries cause persistent pain
Small Fiber Neuropathy
- Alpha-synuclein deposition in peripheral nerves
- Autonomic nerve fiber involvement
- Contributes to neuropathic pain components
| Type |
Description |
Prevalence in PD |
| Musculoskeletal |
Aching, stiffness, related to rigidity |
40-50% |
| Neuropathic |
Burning, tingling, radicular |
20-30% |
| Central |
Thalamic, dysesthetic |
10-15% |
| Akathisia |
Restlessness, inability sit still |
15-20% |
| Nocturnal |
Sleep-related pain, cramps |
30-40% |
Autonomic involvement in PSP is intermediate between PD and MSA:
Cardiovascular
- Orthostatic hypotension occurs in 20-40% of PSP patients
- Typically milder than MSA
- May worsen with disease progression
- Can contribute to falls and syncope
Urinary Function
- Urinary urgency and frequency common
- Nocturia affects up to 60%
- Less severe than MSA but significant impact on quality of life
Gastrointestinal
- Constipation in 50-70% of patients
- Delayed gastric emptying
- May precede motor symptoms by years
Thermoregulation
- Sweating abnormalities
- Heat/cold intolerance
- May relate to hypothalamic involvement
Autonomic failure is a defining feature of MSA:
Neurogenic Orthostatic Hypotension
- Failure of sympathetic vasoconstriction
- Severe drops in blood pressure upon standing
- Can cause syncope, falls, and cerebral hypoperfusion
Urinary Dysfunction
- Urinary incontinence (often early sign)
- Incomplete bladder emptying
- High post-void residual volumes
Erectile Dysfunction
- Often presents early in male patients
- May precede motor symptoms
Respiratory
- Laryngeal stridor from vocal cord paralysis
- Sleep-disordered breathing
- Central apneas
Autonomic symptoms in CBS are less prominent:
- Orthostatic hypotension in ~20%
- Urinary urgency common
- Gastrointestinal involvement similar to PSP
Quantitative Sensory Testing (QST)
- Thermal threshold testing
- Mechanical detection and pain thresholds
- Temporal summation assessment
- Helps distinguish central vs peripheral mechanisms
Functional Imaging
- PET/SPECT studies show altered pain processing
- Reduced dopamine receptor availability in pain circuits
- Functional MRI during pain tasks
Cardiovascular Autonomic Tests
- Head-up tilt table testing
- 24-hour ambulatory blood pressure monitoring
- Heart rate variability analysis
- Baroreflex sensitivity assessment
Sudomotor Testing
- Quantitative sudomotor axon reflex test (QSART)
- Thermoregulatory sweat test
- Skin biopsy for small fiber neuropathy
Bladder Function Studies
- Urodynamics
- Post-void residual measurement
- Urethral pressure profiling
Dopaminergic Agents
- Levodopa may improve pain in some PD patients
- Dopamine agonists have mixed results
- Pain often improves with motor symptom control
Antidepressants
- Duloxetine: SNRI with pain-modulating effects
- Amitriptyline: TCA with strong analgesic properties
- Must consider side effect profiles in elderly
Anticonvulsants
- Gabapentin: Calcium channel modulation
- Pregabalin: Similar mechanism, better bioavailability
- Effective for neuropathic components
Other Agents
- Capsaicin cream for peripheral neuropathic pain
- Lidocaine patches
- Opioids: Use cautiously due to side effects and dependency risk
Orthostatic Hypotension
- Increased salt and fluid intake
- Compression stockings
- Head-of-bed elevation
- Fludrocortisone or midodrine
- Droxidopa (Northera) FDA-approved for neurogenic OH
Urinary Dysfunction
- Anticholinergics (oxybutynin, tolterodine)
- Beta-3 agonists (mirabegron)
- Intermittent catheterization if retention
- Botulinum toxin for detrusor overactivity
Gastrointestinal Issues
- Fiber supplements and laxatives
- Prokinetic agents (metoclopramide)
- Scheduled toileting
- Dietary modifications
This observational study addresses critical knowledge gaps:
Epidemiological Data
- Current prevalence estimates vary widely
- Better characterization will inform clinical practice
- May identify subgroups with distinct mechanisms
Mechanistic Insights
- Correlation with imaging and biomarker data
- Understanding of pain-autonomic relationships
- May reveal novel therapeutic targets
Clinical Outcomes
- Development of standardized assessment tools
- Identification of treatment response predictors
- Foundation for future interventional trials
This study relates to several key pages:
- Multiple movement disorder centers
- Specialized autonomic testing facilities
- Target enrollment: 200-300 participants
- Baseline comprehensive evaluation
- 6-month follow-up
- Annual reassessment for longitudinal cohort
Motor Assessment
- MDS-UPDRS Parts I-III
- Hoehn and Yahr staging
- Timed motor tests
Non-Motor Assessment
- Non-Motor Symptoms Scale (NMSS)
- Parkinson's Disease Questionnaire (PDQ-39)
- Montreal Cognitive Assessment (MoCA)
Autonomic Specific
- SCOPA-AUT
- Orthostatic vital signs
- Bladder/bowel diaries
Pain Specific
- Visual Analog Scale (VAS)
- King's Parkinson's Disease Pain Scale (KPPS)
- McGill Pain Questionnaire
- DN4 for neuropathic features
- Improved awareness of symptom prevalence
- Better assessment practices
- Identification of unmet needs
- Development of targeted therapies
- Personalized treatment approaches
- Biomarker discovery for clinical trials
Pain and autonomic dysfunction represent major challenges in Parkinsonian syndromes. NCT05748028 provides a critical opportunity to systematically characterize these symptoms across disease subtypes. The resulting data will inform clinical management, guide research priorities, and ultimately improve quality of life for patients with Parkinson's disease and atypical parkinsonisms.